Charles Zhou
Stock Analyst at UBS
(0.80)
# 3,701
Out of 4,734 analysts
9
Total ratings
50%
Success rate
-12.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Upgrades: Buy | $67 | $91.33 | -26.64% | 2 | Jan 5, 2024 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $14.29 | +11.97% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $8.20 | +82.93% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.00 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.35 | +4,048.15% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.24 | +3,609.68% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.98 | - | 2 | Jan 22, 2020 |
Futu Holdings
Jan 5, 2024
Upgrades: Buy
Price Target: $67
Current: $91.33
Upside: -26.64%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $14.29
Upside: +11.97%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $8.20
Upside: +82.93%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.00
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.35
Upside: +4,048.15%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.24
Upside: +3,609.68%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.98
Upside: -